Scripps Research develops new class of molecules for drug discovery

The new approach combines synthetic chemistry with advanced screening technologies which would expand the number of provocative synthetic compounds available to explore as potential drug candidates.

In addition, the approach overcomes the substantial molecular limitations associated with state-of-the-art approaches in small molecule synthesis and screening.

The research is led by Scripps Research Associate Professor Glenn Micalizio who said the divergence in structure between natural products and commercially available synthetics is the main focus of their inquiry.

"Why should we limit discovery of therapeutic leads to compound collections that are influenced by concerns relating to commercial availability and compatibility with an artificial set of constraints associated with the structure of modern screening centers," Micalizio added.